IDEC/Genentech's Anti-CD20 Antibody In Phase III Soon?

26 March 1995

Genentech and IDEC Pharmaceuticals have signed an agreement to collaborate on the development of IDEC's monoclonal antibody targeting CD20, a potential treatment for non-Hodgkin's B cell lymphoma. IDEC-C2B8 is expected to enter Phase III clinical trials by mid-1995, according to Genentech.

As part of the agreement, Genentech also gains the option to extend the collaboration to include two radioconjugates for the treatment of B-cell lymphomas, IDEC-Y2B8 and IDEC-In2B8, which are currently in Phase I/II testing. The two companies may also develop IDEC-C2B8 for other B-cell cancers, including chronic lymphocytic leukemia. Genentech has also licensed from IDEC a technology base relating to a Chinese hamster ovary cell gene expression system which has the potential to reduce the time and cost of product development.

Phase II results of a trial with IDEC-C2B8 have demonstrated that the antibody initiate tumor shrinkage in 22 out of 34 patients with relapsed low-grade or follicular non-Hodgkin's B-cell lymphoma (Marketletter November 4, 1994). Of the patients who showed shrinkage, three exhibited a complete response, 13 had a partial response (tumor shrinkage >50%) and six had minor responses (shrinkage >25% but <50%). Response durations ranged from 4.4 to 9.2 months. The results showed a response rate similar to that produced by single-agent chemotherapy, said IDEC, but with few of the toxicities associated with these treatments.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight